Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 61 of 95, showing 5 Applications out of 474 total, starting on record 301, ending on 305

# Protocol No Study Title Investigator(s) & Site(s)

301.

ECCT/18/04/02   Maternal Influenza Vaccine Study
    Impact of HIV Infection and Malaria Parasitemia on Immunogenicity of Inactivated Influenza Vaccine in Pregnant Women and on Mother-to-Child Vaccine-induced Antibody Transfer   
Principal Investigator(s)
1. Sandra S Chaves
Site(s) in Kenya
1. Siaya County Referral Hospital (Siaya county)
2. Bondo Sub-County Hospital (Siaya county)
 
View

302.

ECCT/18/04/01   CKAF156 STUDY
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. KEMRI CDC (Siaya county)
2. Walter Reed Project (Kisumu county)
 
View

303.

ECCT/18/03/01   JiPime JiPrEP (HIVST Study)
    HIV self-testing to improve the efficiency of PrEP delivery.   
Principal Investigator(s)
1. Kenneth Kairu Ngure
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA)
 
View

304.

ECCT/18/01/01   Mal 094
    Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age.   
Principal Investigator(s)
1. Aaron Samuels
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral hospital (Siaya county)
2. Ngiya Health Center (Siaya county)
3. Kogelo Health Center (Siaya county)
4. Tingwangi (Siaya county)
5. Mulaha (Siaya county)
6. Nyathengo (Siaya county)
7. Bal Olengo (Siaya county)
 
View

305.

ECCT/17/11/01   MTN 034
    MTN 034   A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population   
Principal Investigator(s)
1. ESTHER MUMBI MAKANGA
Site(s) in Kenya
KISUMU CRS
 
View